1. Home
  2. ITRN vs GERN Comparison

ITRN vs GERN Comparison

Compare ITRN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ITRN

Ituran Location and Control Ltd.

HOLD

Current Price

$53.18

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.54

Market Cap

911.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRN
GERN
Founded
1994
1990
Country
Israel
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
911.0M
IPO Year
2005
1996

Fundamental Metrics

Financial Performance
Metric
ITRN
GERN
Price
$53.18
$1.54
Analyst Decision
Strong Buy
Hold
Analyst Count
3
3
Target Price
$60.67
$2.17
AVG Volume (30 Days)
144.7K
10.5M
Earning Date
05-26-2026
05-06-2026
Dividend Yield
3.61%
N/A
EPS Growth
N/A
51.85
EPS
N/A
N/A
Revenue
N/A
$1,065,000.00
Revenue This Year
$12.38
$26.91
Revenue Next Year
$8.21
$43.75
P/E Ratio
$16.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.71
$1.04
52 Week High
$68.30
$2.01

Technical Indicators

Market Signals
Indicator
ITRN
GERN
Relative Strength Index (RSI) 40.51 55.72
Support Level $47.78 $1.44
Resistance Level $53.33 $1.69
Average True Range (ATR) 1.98 0.11
MACD -0.01 0.01
Stochastic Oscillator 28.45 74.42

Price Performance

Historical Comparison
ITRN
GERN

About ITRN Ituran Location and Control Ltd.

Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: